Sarepta Therapeutics Announces Clinical Hold on Micro-Dystrophin Gene Therapy Trial
This afternoon Sarepta Therapeutics, Inc. announced that the micro-dystrophin Phase 1/2a gene therapy trial was placed on clinical hold by the FDA as the result of an out-of-specification production lot. The company was notified by the Research…Learn More